BioSpace News Archive

Can-Fite BioPharma Ltd. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,963,637 American Depositary Shares, having exercise prices ranging from $6.00 to $5.50 per ADS, issued by Can-Fite in December 2021 and January 2023, at a reduced exercise price of $1.53 per share.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.

Greenwich LifeSciences, Inc. announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximately 51 months from date of the Company’s IPO.

iTeos Therapeutics, Inc. today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET.

Organon announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.

Ardelyx, Inc. today announced that Ardelyx management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in New York City.

Numinus Wellness Inc. the quarter and year ended August 31, 2023, after market close on Wednesday November 29, 2023.

MedGenome, a global partner for comprehensive multiomics solutions, is pleased to announce a grant for De Novo Genome Assembly and Annotation, in collaboration with PacBio, a pioneer in long-read sequencing.

A newly published study was designed to evaluate the safety and effectiveness of an Elastic Scattering Spectroscopy (ESS) device, the DermaSensor device, in assessing skin lesions suggestive of skin cancer.